{
  "docId": "019de077-880d-703f-ad59-c0ee1df8dfeb",
  "docSlug": "3a2edb97bafa9f0a0205c3f0e878214f",
  "documentTitle": "Legend Biotech | Investor Presentation Deck | 26 slides",
  "authorId": "legend-biotech",
  "authorName": "Legend Biotech",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 26,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes Kaplan-Meier survival curve data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/7",
  "deckHref": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb",
  "deckJsonHref": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json",
  "deckAnchorHref": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Kaplan-Meier survival curve showing CARVYKTI vs SOC",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62ab2db1-b1f5-4f9d-b5f2-cf27e8c53b1f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": "One-time infusion significantly prolonged overall survival and improved quality of life. 45% reduction in risk of death with CARVYKTI® vs SOC in patients with lenalidomide-refractory MM after 1–3 prior LOT. Safety profile consistent with previous analysis.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84f895ca-c948-4ed1-9464-12b37985aa46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1. Mateos, et al. Overall Survival (OS) With Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care (SoC) in Lenalidomide (Len)-Refractory Multiple Myeloma (MM): Phase 3 CARTITUDE-4 Study Update. 2. San-Miguel J, et al.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa1ce93d-d6d3-4c9e-bbde-e1da83ae2b3a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "CARVYKTI® - First CAR-T in MM to Achieve OS Benefit vs SOC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ed2278b-a284-4711-941e-f8c5550c3876",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 7,
      "from": 7,
      "beatId": "c2be2564-70e4-4fbe-9d0d-c79a920b978f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The solution is introduced on page 7, highlighting CARVYKTI's achievements.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867",
      "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.",
      "position": 1,
      "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}